참고문헌
- Beenken SW, Gizzle WE, Crowe DR, Conner MG, Weiss HL, Sellers MT, et al. Molecular biomarkers for breast cancer prognosis: coexpression of C-erbB-2 of p53. Ann Surg 2001233:630-8 https://doi.org/10.1097/00000658-200105000-00006
- Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol 199917: 1974-82 https://doi.org/10.1200/JCO.1999.17.7.1974
- Hsieh CC, Chow KC, Fahn HJ, Tsai CM, Liu WY, Huang MH, et al. Prognostic significance of HER-2/ neu overexpression in stage I adenocarcinoma of lung. Ann Thorac Surg 1998;66:1159-64 https://doi.org/10.1016/S0003-4975(98)00792-9
- Henengstler JG, Lange J, Kett A, Dornhofer N, Meinert R, Arand M, et al. Contribution of c-erbB-2 and topoisomerase II alpha to chemoresistance in ovarian cancer. Cancer Res 1999;59:3206-14
- David L, Serruca R, Nesland JM, Soares P, Sansonetty F, Holm R, et al. C-erb-B2 expression in primary gastric carcinoma and their metastases. Mod Pathol 1992;5:384-90
- Wester K, Sjostrom A, Torre M, Carlsson J, Malmstrom PU. HER-2: a possible target for therapy of metastatic urinary bladder carcinoma. Acta Oncol 2002;41:282-8 https://doi.org/10.1080/02841860260088836
- Ross JS, Fletcher JA. HER-2/neu(c-erbB-2) gene and protein in breast cancer. Am J Clin Pathol 1999;112 (Suppl 1):S53-67
- Hirsch FR, Varcella-Garcia M, Franklin WA, Veve R, Cehn L, Helfrich B, et al. Evaluation of HER-2/neu gene amplification and protein expression in nonsmall- cell lung carcinomas. Br J Cancer 2002;86: 1449-56 https://doi.org/10.1038/sj.bjc.6600286
- Brabernder J, Danenberg KD, Metzger R, Schneider PM, Park J, Salinga D, et al. Epidermal growth factor receptor and HER-2-neu mRNA expression in non-small-cell lung cancer is correlated with survival. Clin Cancer Res 2001;7:1850-5
- Bunn PA Jr, Helfrich B, Soriano A, Franklin WA, Varella-Garcia M, Hirsch F, et al. Expression of HER-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and relationship to in vitro cytotoxicity by trastuzumab and cytotherapeutic. Clin Cancer Res 2001;7:3239-50
- Weidman N, Folkman J. Tumoral vascularity as a prognostic factor in cancer. Drug Dev Res 1996;25: 249-65
- Yano T, Tanikawa S, Fujie T, Masutani M, Horie T. Vascular endothelial growth factor expression and neovascularization in non-small cell lung cancer. Eur J Cancer 2000;36:601-9 https://doi.org/10.1016/S0959-8049(99)00327-5
- Brattstrom D, Wester K, Bergqvist M, Hesselius P, Malmstrom PU, Nordgren H, et al. HER-2, EGFR, COX-2 expression status correlated to microvessel density and survival in resected non-small cell lung cancer. Acta Oncol 2004;43:80-6 https://doi.org/10.1080/02841860310017441
-
Izumi Y, Xu L, Tomaso E, Fukumura D, Jain RK. Tumour biology Herceptin
${\circledR}$ acts as an anti-angiogenetic cocktail. Nature 2002;416:279-80 - Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Shinitt SJ. Specificity of Hercep Test in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol 1999;17:1983-7 https://doi.org/10.1200/JCO.1999.17.7.1983
- Lohrisch C, Piccart M. An overview of HER-2. Semin Oncol 2001;28(6 Suppl):3-11
- Hansen HH. An update on management for lung cancer: Acta Oncologica Lecture-Vasteras 21 March 2002. Acta Oncol 2002;41:500-6 https://doi.org/10.1080/02841860214961
- Itakura Y, Sasano H, Shiaga C. Furukawa Y, Shiga K, Mori S, et al. Epidermal growth factor receptor overexpression in esophageal carcinoma: an immunohistochemical study correlated with clinicopathologic findings and DNA amplification. Cancer 1994;74: 795-804 https://doi.org/10.1002/1097-0142(19940801)74:3<795::AID-CNCR2820740303>3.0.CO;2-I
- Newby JC, A'Hern RP, Leek RD, Smith IX, Harris AL, Dowsett M. Immunohistochemical assay for epidermal growth factor receptor on paraffin-embedded sections: validation against ligand-bindingand clinical relevance in breast cancer. Br J Cancer 1995;71: 1237-42 https://doi.org/10.1038/bjc.1995.239
- Riou G, Mathieu MC, Barrois M, Le Bihan ML, Ahomadegbe JC, Benard J, et al. C-erbB-2(HER-2/ neu) gene amplification is a better indicator of poor prognosis than protein over-expression in operable breast-cancer patients. Int J Cancer 2001;95:266-70 https://doi.org/10.1002/1097-0215(20010720)95:4<266::AID-IJC1045>3.0.CO;2-E
- Allred DC, Swanson PE. Testing for erbB-2 by immunohistochemistry in breast cancer. Am J Clin Pathol 2000;113:171-5 https://doi.org/10.1309/9X6X-1EL6-5QB1-YLD2
- Solbach C, Roller M, Budischewski K, Loibl S, Nicoletti M, Stegmueller M, et al. EGFR and Her2/ neu overexpressing tumors: independent collectives for treatment of breast cancer by specific monoclonal antibody-therapy. J Cancer Res Clin Oncol 2003;129: 250-1
-
Shak S. Overview of the trastuzumab(Herceptin
$^{\circledR}$ ) anti HER-2 monoclonal antibody clinical program in HER-2 overexpressing metastatic breast cancer. Semin Oncol 1999;26:71-7 - Nahta R, Trent S, Yang C, Schmidt EV. Epidermal growth factor receptor expression is a candidate target of the synergistic combination of trastuzumab and flavopiridol in breast cancer. Cancer Res 2003; 63:3626-31
- Brabender J, Danenberg KD, Metzger R, Schneider PM, Park J, Salonga D, et al. Epidermal growth factor receptor andmRNA expression in non small cell lung cancer is correlated with survival. Clin Cancer Res 2001;7:1850-5
- Korrapati V, Gaffney M, Larsson LG, Nunno LD, Riggs M, Beissner RS, et al. Effects of HER-2/neu expression on survival in non small cell lung cancer. Clin Lung Cancer 2001;2:216-9 https://doi.org/10.3816/CLC.2001.n.006
- Folkman J, Watson K,Ingiber D, Hanahan D. Induction of angiogenesis during the transitionfrom hyperplasia to neoplasia.1989;339:58-61 https://doi.org/10.1038/339058a0
- Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and this receptor, KDR, correlates with vascularity, metastasis and proliferation of humancancer. Cancer Res 1995;55:3964-8
- Kerbel RS, Klement G, Prichard KI, Kamen B. Continuous low-dose anti-angiogenic/metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann Oncol 2002;13:12-5 https://doi.org/10.1093/annonc/mdf093